LSE:GSKPharmaceuticals
GSK (LSE:GSK) Seeks European Expansion Of RSV Vaccine To Adults 18 And Older
Recently, GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV vaccine, Arexvy, to adults aged 18 and older. This announcement likely supported the company's 14% share price increase last month, alongside positive movements such as the FDA's review of linerixibat and early success in Tebipenem HBr trials. These advancements contrast the broader market, which experienced turbulence amid geopolitical tensions and surging oil...